All‐cause mortality · patients with myocardial infarction
It is very uncertain whether lidocaine changes all‐cause mortality compared with mexiletine (very low certainty).
1 finding from 1 review
All‐cause mortality · patients with myocardial infarction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · patients with myocardial infarction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · patients with myocardial infarction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · patients with myocardial infarction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · patients with myocardial infarction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · patients with myocardial infarction
It is very uncertain whether lidocaine changes all‐cause mortality compared with disopyramide (very low certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality · preterm or low birth weight infants
The intervention showed no clear difference in all‐cause mortality (moderate certainty).
1 finding from 1 review
All‐cause mortality WMD of · Adults (aged 40 or over) with COPD presenting with 1 or more exacerbations in the previous year. The 2 larger studies (Albert 2011; Sethi…
Antibiotics showed no clear difference in all‐cause mortality WMD of compared with placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
Infection‐related mortality · cancer patients receiving myelotoxic chemotherapy
1 finding from 1 review
Intervention not reported
Infection‐related mortality · cancer patients receiving myelotoxic chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Maternal mortality ‐ not reported · women in the third stage of labour
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Maternal mortality ‐ not reported · women in the third stage of labour
1 finding from 1 review
Maternal mortality ‐ not reported · women in the third stage of labour
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality within the longest · Children having heart surgery with cardiopulmonary bypass
Glucocorticoid showed no clear difference in all‐cause mortality at longest compared with placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
Early mortality Rates of patients · breast cancer patients undergoing chemotherapy
The intervention may leads to lower early mortality Rates of patients (low certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality ‐ not reported · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
In‐hospital postoperative mortality · Children having heart surgery with cardiopulmonary bypass
Glucocorticoid showed no clear difference in in‐hospital postoperative mortality compared with placebo (moderate certainty).
1 finding from 1 review
Cardiovascular mortality · Children having heart surgery with cardiopulmonary bypass
Glucocorticoid showed no clear difference in cardiovascular mortality at longest compared with placebo (moderate certainty).
1 finding from 1 review
Mortality at 6 months: main analysis · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Vitamin K antagonist (VKA) prophylaxis showed no clear difference in mortality at 6 months: main analysis compared with no prophylaxis (moderate certainty).
1 finding from 1 review